{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:47Z","timestamp":1794047447089,"version":"4.8.0"},"reference-count":75,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Children with Down syndrome (DS, trisomy 21) are at a significantly higher risk of developing acute leukemia compared to the overall population. Many studies investigating the link between trisomy 21 and leukemia initiation and progression have been conducted over the last two decades. Despite improved treatment regimens and significant progress in iden - tifying genes on chromosome 21 and the mechanisms by which they drive leukemogenesis, there is still much that is unknown. A focused group of scientists and clinicians with expertise in leukemia and DS met in October 2022 at the J\u00e9r\u00f4me Lejeune Foundation in Paris, France for the 1st International Symposium on Down Syndrome and Leukemia. This meeting was held to discuss the most recent advances in treatment regimens and the biology underlying the initiation, progression, and relapse of acute lymphoblastic leukemia and acute myeloid leukemia in children with DS. This review provides a summary of what is known in the field, challenges in the management of DS patients with leukemia, and key questions in the field.<\/jats:p>","DOI":"10.3324\/haematol.2023.283225","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T03:59:43Z","timestamp":1689220783000},"page":"2570-2581","source":"Crossref","is-referenced-by-count":68,"title":["Down syndrome and leukemia: from basic mechanisms to clinical advances"],"prefix":"10.3324","volume":"108","author":[{"given":"Andr\u00e9","family":"Baruchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Cuartero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Hitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Izraeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ryeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvin","family":"Wagenblast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"51987","doi-asserted-by":"crossref","unstructured":"Hasle H, Clemmensen IH, Mikkelsen M.. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet. 2000; 355(9199):165-169.","DOI":"10.1016\/S0140-6736(99)05264-2"},{"key":"51988","doi-asserted-by":"crossref","unstructured":"Hitzler JK, Zipursky A.. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005; 5(1):11-20.","DOI":"10.1038\/nrc1525"},{"key":"51989","doi-asserted-by":"crossref","unstructured":"Labuhn M, Perkins K, Matzk S. Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome. Cancer Cell. 2019; 36(3):340.","DOI":"10.1016\/j.ccell.2019.08.014"},{"key":"51990","doi-asserted-by":"crossref","unstructured":"Yoshida K, Toki T, Okuno Y. The landscape of somatic mutations in Down syndrome\u2013related myeloid disorders. Nat Genet. 2013; 45(11):1293-1299.","DOI":"10.1038\/ng.2759"},{"key":"51991","doi-asserted-by":"crossref","unstructured":"Malinge S, Bliss-Moreau M, Kirsammer G. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012; 122(3):948-962.","DOI":"10.1172\/JCI60455"},{"key":"51992","doi-asserted-by":"crossref","unstructured":"Nikolaev SI, Garieri M, Santoni F. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun. 2014; 5:4654.","DOI":"10.1038\/ncomms5654"},{"key":"51993","doi-asserted-by":"crossref","unstructured":"Brown PA, Ji L, Xu X. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR\/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents\/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children\u2019s Oncology Group Study AALL1331. Blood. 2019; 134(Suppl_2):LBA-1.","DOI":"10.1182\/blood-2019-132435"},{"key":"51994","doi-asserted-by":"crossref","unstructured":"Lane AA, Chapuy B, Lin CY. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014; 46(6):618-623.","DOI":"10.1038\/ng.2949"},{"key":"51995","doi-asserted-by":"crossref","unstructured":"Jardine L, Webb S, Goh I. Blood and immune development in human fetal bone marrow and Down syndrome. Nature. 2021; 598(7880):327-331.","DOI":"10.1038\/s41586-021-03929-x"},{"key":"51996","doi-asserted-by":"crossref","unstructured":"Wagenblast E, Ara\u00fajo J, Gan OI. Mapping the cellular origin and early evolution of leukemia in Down syndrome. Science. 2021; 373(6551):eabf6202.","DOI":"10.1126\/science.abf6202"},{"key":"51997","doi-asserted-by":"crossref","unstructured":"Schwartzman O, Savino AM, Gombert M. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci U S A. 2017; 114(20):E4030-E4039.","DOI":"10.1073\/pnas.1702489114"},{"key":"51998","doi-asserted-by":"crossref","unstructured":"Laurent AP, Siret A, Ignacimouttou C. Constitutive activation of RAS\/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell leukemia targeting RAS\/MAPK pathway in DS-ALL. Clin Cancer Res. 2020; 26(13):3307-3318.","DOI":"10.1158\/1078-0432.CCR-19-3519"},{"key":"51999","doi-asserted-by":"crossref","unstructured":"Buitenkamp TD, Izraeli S, Zimmermann M. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014; 123(1):70-77.","DOI":"10.1182\/blood-2013-06-509463"},{"key":"52000","doi-asserted-by":"crossref","unstructured":"Ceppi F, Stephens D, den Hollander BS. Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016; 63(11):1949-1953.","DOI":"10.1002\/pbc.26127"},{"key":"52001","doi-asserted-by":"crossref","unstructured":"Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. Genet Med. 2016; 18(11):1151-1157.","DOI":"10.1038\/gim.2016.23"},{"key":"52002","doi-asserted-by":"crossref","unstructured":"Hasle H, Kline RM, Kjeldsen E. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype. Blood. 2022; 139(21):3159-3165.","DOI":"10.1182\/blood.2021011463"},{"key":"52003","doi-asserted-by":"crossref","unstructured":"Satg\u00e9 D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M.. A tumor profile in Down syndrome. Am J Med Genet. 1998; 78(3):207-216.","DOI":"10.1002\/(SICI)1096-8628(19980707)78:3<207::AID-AJMG1>3.0.CO;2-M"},{"key":"52004","doi-asserted-by":"crossref","unstructured":"Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M.. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer. 2006; 118(7):1769-1772.","DOI":"10.1002\/ijc.21518"},{"key":"52005","doi-asserted-by":"crossref","unstructured":"Osuna-Marco MP, L\u00f3pez-Barahona M, L\u00f3pez-Ibor B, Tejera \u00c1M. Ten reasons why people with Down syndrome are protected from the development of most solid tumors - a review. Front Genet. 2021; 12:749480.","DOI":"10.3389\/fgene.2021.749480"},{"key":"52006","doi-asserted-by":"crossref","unstructured":"Rethor\u00e9 M-O, Rou\u00ebss\u00e9 J, Satg\u00e9 D.. Cancer screening in adults with Down syndrome, a proposal. Eur J Med Genet. 2020; 63(4):103783.","DOI":"10.1016\/j.ejmg.2019.103783"},{"key":"52007","doi-asserted-by":"crossref","unstructured":"Flasinski M, Scheibke K, Zimmermann M. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Adv. 2018; 2(13):1532-1540.","DOI":"10.1182\/bloodadvances.2018018945"},{"key":"52008","doi-asserted-by":"crossref","unstructured":"Uffmann M, Rasche M, Zimmermann M. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017; 129(25):3314-3321.","DOI":"10.1182\/blood-2017-01-765057"},{"key":"52009","doi-asserted-by":"crossref","unstructured":"Hitzler J, Alonzo T, Gerbing R. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021; 138(23):2337-2346.","DOI":"10.1182\/blood.2021012206"},{"key":"52010","doi-asserted-by":"crossref","unstructured":"Tandonnet J, Clavel J, Baruchel A, Nacka F, P\u00e9rel Y.. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003. Pediatr Blood Cancer. 2010; 54(7):927-933.","DOI":"10.1002\/pbc.22515"},{"key":"52011","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Rives S. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023; 41(9):1664-1669.","DOI":"10.1200\/JCO.22.00642"},{"key":"52012","doi-asserted-by":"crossref","unstructured":"Rabin KR, Chen Z, Devidas M. Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): a Children\u2019s Oncology Group (COG) report. J Clin Oncol. 2020; 38(15_suppl):10510.","DOI":"10.1200\/JCO.2020.38.15_suppl.10510"},{"key":"52013","doi-asserted-by":"crossref","unstructured":"Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome\u2013like acute lymphoblastic leukemia. Blood Adv. 2020; 4(1):218-228.","DOI":"10.1182\/bloodadvances.2019000163"},{"key":"52014","doi-asserted-by":"crossref","unstructured":"Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome\u2013like acute lymphoblastic leukemia. Blood. 2017; 130(19):2064-2072.","DOI":"10.1182\/blood-2017-06-743252"},{"key":"52015","doi-asserted-by":"crossref","unstructured":"Tasian SK, Doral MY, Borowitz MJ. Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 2012; 120(4):833-842.","DOI":"10.1182\/blood-2011-12-389932"},{"key":"52016","doi-asserted-by":"crossref","unstructured":"Maude SL, Tasian SK, Vincent T. Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012; 120(17):3510-3518.","DOI":"10.1182\/blood-2012-03-415448"},{"key":"52017","doi-asserted-by":"crossref","unstructured":"Hurtz C, Wertheim GB, Loftus JP. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. J Clin Invest. 2020; 130(7):3637-3653.","DOI":"10.1172\/JCI134424"},{"key":"52018","doi-asserted-by":"crossref","unstructured":"Loh ML, Tasian SK, Rabin KR. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015; 62(10):1717-1724.","DOI":"10.1002\/pbc.25575"},{"key":"52019","doi-asserted-by":"crossref","unstructured":"Tasian SK, Assad A, Hunter DS, Du Y, Loh ML. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the part 1 safety phase. Blood. 2018; 132(Suppl 1):555.","DOI":"10.1182\/blood-2018-99-110221"},{"key":"52020","doi-asserted-by":"crossref","unstructured":"Chien CD, Nguyen SM, Qin H, Jacoby E, Fry TJ. CRLF2\/Tslpr overexpressing acute lymphoblastic leukemia relapse is driven by chemotherapy-induced TSLP from bone marrow stromal cells. Blood. 2015; 126(23):1432-1432.","DOI":"10.1182\/blood.V126.23.1432.1432"},{"key":"52021","doi-asserted-by":"crossref","unstructured":"Bagashev A, Loftus J, Niswander L. P1421: bimodal targeting of cytokine receptor-like factor 2 (CRLF2) with JAK inhibition and chimeric antigen receptor T cell Immunotherapy in Down syndrome acute lymphoblastic leukemia. Hemasphere. 2022; 6(Suppl):1305-1306.","DOI":"10.1097\/01.HS9.0000848544.25019.34"},{"key":"52022","doi-asserted-by":"crossref","unstructured":"Maclean GA, Menne TF, Guo G. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A. 2012; 109(43):17567-17572.","DOI":"10.1073\/pnas.1215468109"},{"key":"52023","doi-asserted-by":"crossref","unstructured":"Chou ST, Opalinska JB, Yao Y. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood. 2008; 112(12):4503-4506.","DOI":"10.1182\/blood-2008-05-157859"},{"key":"52024","doi-asserted-by":"crossref","unstructured":"Banno K, Omori S, Hirata K. Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities. Cell Rep. 2016; 15(6):1228-1241.","DOI":"10.1016\/j.celrep.2016.04.031"},{"key":"52025","doi-asserted-by":"crossref","unstructured":"Hollanda LM, Lima CSP, Cunha AF. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006; 38(7):807-812.","DOI":"10.1038\/ng1825"},{"key":"52026","doi-asserted-by":"crossref","unstructured":"Sankaran VG, Ghazvinian R, Do R. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012; 122(7):2439-2443.","DOI":"10.1172\/JCI63597"},{"key":"52027","doi-asserted-by":"crossref","unstructured":"van Dooijeweert B, Kia SK, Dahl N. GATA-1 defects in Diamond\u2013Blackfan anemia: phenotypic characterization points to a specific subset of disease. Genes. 2022; 13(3):447.","DOI":"10.3390\/genes13030447"},{"key":"52028","doi-asserted-by":"crossref","unstructured":"Labuhn M, Perkins K, Matzk S. Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome. Cancer Cell. 2019; 36(2):123-138.","DOI":"10.1016\/j.ccell.2019.06.007"},{"key":"52029","doi-asserted-by":"crossref","unstructured":"Yoshida K, Toki T, Okuno Y. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013; 45(11):1293-1299.","DOI":"10.1038\/ng.2759"},{"key":"52030","doi-asserted-by":"crossref","unstructured":"de Rooij JDE, Branstetter C, Ma J. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017; 49(3):451-456.","DOI":"10.1038\/ng.3772"},{"key":"52031","doi-asserted-by":"crossref","unstructured":"Roberts I, Alford K, Hall G. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013; 122(24):3908-3917.","DOI":"10.1182\/blood-2013-07-515148"},{"key":"52032","doi-asserted-by":"crossref","unstructured":"Byrska-Bishop M, VanDorn D, Campbell AE. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus. J Clin Invest. 2015; 125(3):993-1005.","DOI":"10.1172\/JCI75714"},{"key":"52033","doi-asserted-by":"crossref","unstructured":"Arkoun B, Robert E, Boudia F. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model. J Clin Invest. 2022; 132(14):e156290.","DOI":"10.1172\/JCI156290"},{"key":"52034","doi-asserted-by":"crossref","unstructured":"Roy A, Cowan G, Mead AJ. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci U S A. 2012; 109(43):17579-17584.","DOI":"10.1073\/pnas.1211405109"},{"key":"52035","doi-asserted-by":"crossref","unstructured":"MacLean GA, McEldoon J, Huang J, Allred J, Canver MC, Orkin SH. Downregulation of endothelin receptor B contributes to defective B cell lymphopoiesis in trisomy 21 pluripotent stem cells. Sci Rep. 2018; 8(1):8001.","DOI":"10.1038\/s41598-018-26123-y"},{"key":"52036","doi-asserted-by":"crossref","unstructured":"Li Z, Chang T-C, Junco JJ. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023; 142(2):172-184.","DOI":"10.1182\/blood.2023019765"},{"key":"52037","doi-asserted-by":"crossref","unstructured":"Gialesaki S, Br\u00e4uer-Hartmann D, Issa H. RUNX1 isoform disequilibrium promotes the development of trisomy 21 associated myeloid leukemia. Blood. 2023; 141(10):1105-1118.","DOI":"10.1182\/blood.2022017619"},{"key":"52038","doi-asserted-by":"crossref","unstructured":"Klusmann J-H, Li Z, B\u00f6hmer K. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010; 24(5):478-490.","DOI":"10.1101\/gad.1856210"},{"key":"52039","doi-asserted-by":"crossref","unstructured":"Kugler E, Birger Y, Yong D. AML-079: the PNT domain of ERG regulates hematopoietic stemness and is required for the maintenance of ERG-induced leukemia. Clin Lymphoma Myeloma Leuk. 2020; 20:S180-S181.","DOI":"10.1016\/S2152-2650(20)30713-8"},{"key":"52040","doi-asserted-by":"crossref","unstructured":"Alejo-Valle O, Weigert K, Bhayadia R. The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood. 2022; 139(5):651-665.","DOI":"10.1182\/blood.2021012231"},{"key":"52041","doi-asserted-by":"crossref","unstructured":"Mowery CT, Reyes JM, Cabal-Hierro L. Trisomy of a Down syndrome critical region globally amplifies transcription via HMGN1 overexpression. Cell Rep. 2018; 25(7):1898-1911.","DOI":"10.1016\/j.celrep.2018.10.061"},{"key":"52042","doi-asserted-by":"crossref","unstructured":"Page EC, Heatley SL, Eadie LN. HMGN1 plays a significant role in CRLF2 driven Down syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene. 2022; 41(6):797-808.","DOI":"10.1038\/s41388-021-02126-4"},{"key":"52043","doi-asserted-by":"crossref","unstructured":"Cabal-Hierro L, van Galen P, Prado MA. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020; 11(1):1406.","DOI":"10.1038\/s41467-020-15221-z"},{"key":"52044","doi-asserted-by":"crossref","unstructured":"Yan F, Li J, Milosevic J. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs. Cancer Discov. 2022; 12(3):792-811.","DOI":"10.1158\/2159-8290.CD-20-1459"},{"key":"52045","doi-asserted-by":"crossref","unstructured":"Grimm J, Bhayadia R, Gack L, Heckl D, Klusmann J-H. Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core. Leukemia. 2022; 36(7):1926-1930.","DOI":"10.1038\/s41375-022-01603-3"},{"key":"52046","doi-asserted-by":"crossref","unstructured":"Stankov MV, El Khatib M, Kumar Thakur B. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia. 2014; 28(3):577-588.","DOI":"10.1038\/leu.2013.264"},{"key":"52047","doi-asserted-by":"crossref","unstructured":"Scheer C, Kratz C, Witt O, Creutzig U, Reinhardt D, Klusmann J-H. Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome. Pediatr Blood Cancer. 2016; 63(9):1677-1679.","DOI":"10.1002\/pbc.26062"},{"key":"52048","doi-asserted-by":"crossref","unstructured":"Tamura A, Ishida T, Saito A. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2018; 65(10):e27284.","DOI":"10.1002\/pbc.27284"},{"key":"52049","doi-asserted-by":"crossref","unstructured":"Becktell K, Houser K, Burke MJ. Epigenetic therapy in a patient with Down sndrome and refractory acute myeloid leukemia. J Pediatr Hematol Oncol. 2019; 41(1):e38-e40.","DOI":"10.1097\/MPH.0000000000001158"},{"key":"52050","doi-asserted-by":"crossref","unstructured":"Baek K-H, Zaslavsky A, Lynch RC. Down\u2019s syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009; 459(7250):1126-1130.","DOI":"10.1038\/nature08062"},{"key":"52051","doi-asserted-by":"crossref","unstructured":"Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc Min-mediated tumours in mouse models of Down\u2019s syndrome. Nature. 2008; 451(7174):73-75.","DOI":"10.1038\/nature06446"},{"key":"52052","doi-asserted-by":"crossref","unstructured":"Zorick TS, Mustacchi Z, Bando SY. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet. 2001; 9(11):811-814.","DOI":"10.1038\/sj.ejhg.5200721"},{"key":"52053","doi-asserted-by":"crossref","unstructured":"Reynolds LE, Watson AR, Baker M. Tumour angiogenesis is reduced in the Tc1 mouse model of Down\u2019s syndrome. Nature. 2010; 465(7299):813-817.","DOI":"10.1038\/nature09106"},{"key":"52054","doi-asserted-by":"crossref","unstructured":"Ling T, Zhang K, Yang J, Gurbuxani S, Crispino JD. Gata1s mutant mice display persistent defects in the erythroid lineage. Blood Adv. 2023; 7(13):3253-3264.","DOI":"10.1182\/bloodadvances.2022008124"},{"key":"52055","doi-asserted-by":"crossref","unstructured":"Li Z, Godinho FJ, Klusmann J-H, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):1619-1631.","DOI":"10.1038\/ng1566"},{"key":"52056","doi-asserted-by":"crossref","unstructured":"Ling T, Birger Y, Stankiewicz MJ. Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis. Blood. 2019; 134(19):1619-1631.","DOI":"10.1182\/blood.2019001234"},{"key":"52057","doi-asserted-by":"crossref","unstructured":"Merkenschlager M, Nora EP. CTCF and cohesin in genome folding and transcriptional gene regulation. Annu Rev Genomics Hum Genet. 2016; 17:17-43.","DOI":"10.1146\/annurev-genom-083115-022339"},{"key":"52058","doi-asserted-by":"crossref","unstructured":"Cuartero S, Weiss FD, Dharmalingam G. Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation. Nat Immunol. 2018; 19(9):932-941.","DOI":"10.1038\/s41590-018-0184-1"},{"key":"52059","doi-asserted-by":"crossref","unstructured":"Stik G, Vidal E, Barrero M. CTCF is dispensable for immune cell transdifferentiation but facilitates an acute inflammatory response. Nat Genet. 2020; 52(7):655-661.","DOI":"10.1038\/s41588-020-0643-0"},{"key":"52060","doi-asserted-by":"crossref","unstructured":"Cuartero S, Innes AJ, Merkenschlager M.. Towards a better understanding of cohesin mutations in AML. Front Oncol. 2019; 9:867.","DOI":"10.3389\/fonc.2019.00867"},{"key":"52061","doi-asserted-by":"crossref","unstructured":"Bhansali RS, Rammohan M, Lee P. DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3. J Clin Invest. 2021; 131(1):e135937.","DOI":"10.1172\/JCI135937"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283225\/75815","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283225\/76066","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11156\/75815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:27Z","timestamp":1794045867000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":75,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283225","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}